Montefiore Medical Center

Hospital


Location: New York NY, United States (USA) (US) US

ISNI: 0000000121520791

ROR: https://ror.org/044ntvm43

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis (2022) Efe C, Tascilar K, Gerussi A, Bolis F, Lammert C, Ebik B, Stättermayer AF, et al. Journal article MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial (2022) Hausler KG, Eichner FA, Heuschmann PU, Fiebach JB, Engelhorn T, Blank B, Callans D, et al. Journal article Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis (2021) Efe C, Lammert C, Tascilar K, Dhanasekaran R, Ebik B, Higuera-De La Tijera F, Caliskan AR, et al. Journal article Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Sample collection for laboratory-based study of the nasal airway and sinuses: a research compendium (2019) Massey CJ, Del Valle FD, Abuzeid WM, Levy JM, Müller SK, Levine CG, Smith SS, et al. Journal article Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) House AA, Wanner C, Sarnak MJ, Pina IL, Mcintyre CW, Komenda P, Kasiske BL, et al. Journal article Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial (2018) Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, et al. Journal article Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al. Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution